Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BackgroundAcute and chronic exposure to cannabinoids has been associated with cognitive deficits, a higher risk for schizophrenia and other drug abuse. However, the precise mechanism underlying such effects is not known. Preclinical studies suggest that cannabinoids modulate brain-derived neurotrophic factor (BDNF). Accordingly, we hypothesized that Δ9-tetrahydrocannabinol (Δ9-THC), the principal active component of cannabis, would alter BDNF levels in humans.Materials and methodsHealthy control subjects (n = 14) and light users of cannabis (n = 9) received intravenous administration of (0.0286 mg/kg) Δ9-THC in a double-blind, fixed order, placebo-controlled, laboratory study. Serum sampled at baseline, after placebo administration, and after Δ9-THC administration was assayed for BDNF using ELISA.ResultsΔ9-THC increased serum BDNF levels in healthy controls but not light users of cannabis. Further, light users of cannabis had lower basal BDNF levels. Δ9-THC produced psychotomimetic effects, perceptual alterations, and “high” and spatial memory impairments.ImplicationsThe effects of socially relevant doses of cannabinoids on BDNF suggest a possible mechanism underlying the consequences of exposure to cannabis. This may be of particular importance for the developing brain and also in disorders believed to involve altered neurodevelopment such as schizophrenia. Larger studies to investigate the effects of cannabinoids on BDNF and other neurotrophins are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Binder (2004) · doi:10.1080/08977190410001723308 · Cited by 1,481
Transport of brain-derived neurotrophic factor across the blood–brain barrier
Pan, W., Banks, W. A., Fasold, M. B., Bluth, J., & Kastin, A. J. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00141-5 · Cited by 1,354
The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation
Kay, S. R., Opler, L. A., & Lindenmayer, J.-P. (1989) · British Journal of Psychiatry · doi:10.1192/s0007125000291514 · Cited by 1,016 · cited 1×
“Psychotomimetic effects were assessed with the Positive and Negative Syndrome Scale (PANSS; Kay et al. 1989) and Clinician Administered Dissociative Symptoms Scale (CADSS) (Bremner et al. 1998).”
MethodThe neurodevelopmental model of schizophrenia: update 2005
Rapoport, J. L., Addington, A. M., Frangou, S., & Psych, M. R. C. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001642 · Cited by 993 · cited 1×
“One view of schizophrenia is that it is a neurodevelopmental disorder (Rapoport et al. 2005; Weinberger 1996), and neurotrophic factors have been implicated in its pathophysiology (Buckley et al. 2007; Pillai 2008; Shoval and Weizman 2005).”
FERRIS, L. T., WILLIAMS, J. S., & SHEN, C.-L. (2007) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31802f04c7 · Cited by 849 · cited 2×
“While limited, the sample size of this preliminary study is comparable to that of some published reports on the effects of interventions (e.g., exercise, electroconvulsive therapy) on serum BDNF (Ferris et al. 2007; Gronli et al. 2007; Rojas Vega et al. 2006; Tang et al. 2008).”
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 4×
“3, Δ9-THC produced statistically significant increases (all p 0.0001) in positive symptoms of psychosis (PANSS), perceptual alterations (CADSS), and subjective high (VAS).”
MethodInfluentialBrain-derived Neurotrophic Factor Is Stored in Human Platelets and Released by Agonist Stimulation
Fujimura, H., Chen, R., Nakamura, T., Nakahashi, T., Kambayashi, J.-I., Sun, B., Altar, C., & Tandon, N. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613072 · Cited by 777 · cited 2×
“Alternatively, increases in serum BDNF may be related to the effects of Δ(9)-THC on platelets (Fujimura et al. 2002; Radka et al. 1996), lymphocytes (Kerschensteiner et al.”
Neuronal plasticity and survival in mood disorders
Duman, R. S., Malberg, J., Nakagawa, S., & D’Sa, C. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00935-5 · Cited by 652
Poduslo, J. F., & Curran, G. L. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00250-v · Cited by 614 · cited 1×
“…by some (Pardridge et al. 1994), experimental studies demonstrate that peripherally administered BDNF passes through the blood–brain barrier (Pan et al. 1998; Poduslo and Curran 1996) and can have central effects (Berger et al. 2004; Muller et al. 2008; Schabitz et al. 2000; Schabitz et al. 2007).”
Vascular endothelial cells synthesize and secrete brain‐derived neurotrophic factor
Nakahashi, T., Fujimura, H., Altar, C. A., Li, J., Kambayashi, J.-I., Tandon, N. N., & Sun, B. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01302-8 · Cited by 430 · cited 1×
“Alternatively, increases in serum BDNF may be related to the effects of Δ9-THC on platelets (Fujimura et al. 2002; Radka et al. 1996), lymphocytes (Kerschensteiner et al. 1999; Noga et al. 2003), and endothelial cells (Nakahashi et al. 2000).”
Synaptic plasticity and mood disorders
Duman, R. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001016 · Cited by 363 · cited 1×
“Similarly, if decreased neurogenesis in the hippocampus is a mechanism underlying mood changes, such as depression (Duman 2002; Duman et al. 2000), then cannabis exposure may promote the development of mood disorders by altering BDNF and consequently neurogenesis.”
Rojas Vega, S., Strüder, H. K., Vera Wahrmann, B., Schmidt, A., Bloch, W., & Hollmann, W. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.105 · Cited by 357
Cited by
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606
Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?
Hillard, C. J. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.130 · Cited by 445
Heyman, E., Gamelin, F.-X., Goekint, M., Piscitelli, F., Roelands, B., Leclair, E., Di Marzo, V., & Meeusen, R. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.09.017 · Cited by 427
“In line with our interpretation, an acute peripheral administration of a CB1 receptor agonist was shown to induce an increase in serum BDNF levels in humans, hypothetically through activation of the ERK signaling pathway (D’Souza et al., 2009).”
Cannabis and adolescent brain development.
Lubman, D. I., Cheetham, A., & Yücel, M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.009 · Cited by 360
Metadata
- Authors
- D’Souza, D. C., Pittman, B., Perry, E., & Simen, A.
- Venue
- Psychopharmacology
- Published
- 2008-09-21
- Volume
- 202
- Issue
- 4
- Pages
- 569-578
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2058449221
- Cited by
- 117
- References
- 13
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.